Contract 75A50119D00018
Mapp Biopharmaceutical, Inc. · Department Of Health And Human Services · July 18, 2024
Mapp Biopharmaceutical, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on July 18, 2024 for an undisclosed amount of work in research and development in biotechnology (except nanobiotechnology). It was awarded under full and open competition. The contract has been modified 4 times since the base award It uses cost-plus contract pricing. The most recent modification was on July 30, 2025. If all options are exercised, the contract could reach $50.10 million.
Contract details
- PIID
- 75A50119D00018
- Award type
- Indefinite Delivery / Requirements
- Pricing
- Cost Plus Fixed Fee
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- First action
- July 18, 2024
- Latest action
- July 30, 2025
Description
THE PURPOSE OF THIS NO-COST MODIFICATION IS TO 1. EXTEND CLIN 0003 PERIOD OF PERFORMANCE FROM 30 SEP 2025 TO 30 JUN 2026 AND 2. REVISE PRIMARY AND ALTERNATE COR. 3. TRANSFER GFP
Modification timeline
-
July 30, 2025Mod P00020 · Other Administrative Action$37.51M
-
April 18, 2025Mod P00019$0
-
August 29, 2024Mod P00016 · Other Administrative ActionNO COST MODIFICATION TO REVISE THE STATEMENT OF WORK.$37.51M
-
August 15, 2024Mod P00015 · Other Administrative ActionNO COST MODIFICATION TO REVISE THE PROVISIONAL RATES FOR SECTION G.7 INDIRECT COST RATES.$37.51M
-
July 18, 2024Mod P00014 · Other Administrative ActionUNILATERAL NO COST MODIFICATION TO CORRECT DELIVERY DATE ERRORS WITHIN PRISM, TO ENABLE MAPP BIOPHARMACEUTICAL'S INVOICING IN THE INVOICE PROCESSING PLATFORM (IPP) SYSTEM.$37.51M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50119D00018?
Contract 75A50119D00018 is a federal contract awarded to Mapp Biopharmaceutical, Inc. by Department Of Health And Human Services on July 18, 2024 for an undisclosed amount of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 4 times since the base award.
Who won contract 75A50119D00018?
Mapp Biopharmaceutical, Inc. won contract 75A50119D00018 from Department Of Health And Human Services.
How much is contract 75A50119D00018 worth?
Contract 75A50119D00018 has obligated $0 to date but carries a potential ceiling of $50.10 million if fully funded and all options are exercised.